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Abstract
Background: Human Epidermal Growth Factor (Her-2/neu) has strong therapeutic implications in certain cancers
like breast and gastric cancer. Literature on its frequency in colorectal cancer is scarce. In this study, we have
investigated the frequency of Her-2/neu expression in colorectal adenocarcinomas and its association with various
clinicopathological variables.
Methods: A total of 95 patients who underwent colonoscopic biopsy or colectomy were studied after Institutional
Ethical Approval. Hematoxylin & eosin (H&E) staining was performed on all the tissue sections. Expression of Her-2/
neu was investigated by immunohistochemistry using α-Her-2 antibody. In order to quantify Her-2/neu expression,
three criterias were applied that includes the pattern of staining, intensity of staining and percentage of tumor cells
stained. Furthermore, its association was seen with various clinicopathological variables including age, gender,
histopathological type, grade and stage of the tumor. Data was entered and analyzed using SPSS version 21. A p-
value of < 0.05 was considered as significant.
Results: From the total of 95 cases, 75 (78.9 %) cases showed Her-2/neu expression. Pattern of Her-2/neu staining
was significantly associated with the grade of colorectal cancer depicting cytoplasmic Her-2/neu expression
higher in low grade (50 %) while membranous Her-2/neu expression more in high grade colorectal cancer (45 %)
(P-value = 0.030). Pattern of Her-2/neu staining was also significantly associated with the type of colorectal cancer
representing membranous Her-2/neu expression to be more common in mucinous type (38.5 %) while cytoplasmic
Her-2/neu expression to be more frequent in non mucinous type (42.7 %) of colorectal cancer (p-value = 0.024).
We observed a significant association between percentage of cells stained & tumor type, with score 3+ maximum in
non mucinous type of colorectal cancer (p-value = 0.006).
Conclusion: Her2/neu is considerably expressed in colorectal adenocarcinoma in Pakistani population. Our findings
indicate a significant strong association of cytoplasmic Her-2/neu expression with low grades and membranous Her-2/
neu expression with high grades of colorectal cancer. These findings add to the body of information & may help in
conducting clinical trials in future to explore its therapeutic significance as well.
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Background
Gastrointestinal malignancies are amongst the major
oncological problems worldwide. Colorectal cancer is
the 3rd most common cancer across the globe [1]. A rise
in incidence and mortality rates of colorectal cancers are
illustrated in Asia [2]. In Pakistan, a low but rising inci-
dence of colorectal cancer at young age with advanced
stages is being consistently observed in the recent past
[3]. Rising incidence and high mortality of colorectal
cancer demands for a need of newer therapeutic targets
to improve the survival of the patients.
Human Epidermal Growth Factor (Her-2/neu) is a
proto-oncogene located on chromosome 17q21 that en-
codes ErbB-2 [4]. Over-expression of Her-2/neu has
been notably associated with increased cellular survival,
increased proliferation and decreased apoptotic potential
of cells leading to malignant transformation and main-
tenance of the associated malignancy [5]. Presence of
Her-2/neu is strongly implicated in certain cancers in-
cluding breast & stomach. Trastuzumab, a monoclonal
antibody against Her-2/neu, has shown a good prognosis
in Her-2/neu positive breast cancer patients [6]. Re-
cently, α-Her-2 targeted therapy has also been approved
for metastatic gastric adenocarcinomas [7, 8].
A very scarce data is available particularly from our re-
gion to indicate expression of Her-2/neu in patients with
colorectal adenocarcinomas. Overexpression of Her-2/
neu in colorectal cancer shows a wide range of variabil-
ity between 0-84 % in different studies [9].
Her-2/neu expresses itself in either membranous as
well as cytoplasmic forms with different clinical implica-
tions in different cancers. For instance, cytoplasmic ex-
pression of Her-2/neu in breast cancer does occur but it
has been regarded as irrelevant since the monoclonal
antibodies approved for its treatment, targets only mem-
branous forms [9]. In contrast, several studies reported
that Her-2/neu expression to be membranous as well as
cytoplasmic in colorectal adenocarcinoma [10, 11].
Moreover, literature supports that cytoplasmic Her-2/
neu expression in colorectal carcinoma could be associ-
ated with survival prognosis [9]. The definitive cause of
cytoplasmic expression of Her-2/neu still remains un-
clear but upregulation of promoter binding proteins
leading to an increase in Her-2/neu production provides
some evidence for the identity of cytoplasmic expression
of Her-2/neu in colorectal cancer [9]. Use of α-Her-2
therapy in the treatment of colorectal cancer patients
has been less extensively investigated. A clinical trial
conducted showed a low positivity (8 %) of Her-2/neu
expression but these patients responded to Trastuzumab
therapy [12].
However, and alarmingly, Her-2/neu testing in colo-
rectal adenocarcinoma has not gained its popularity in
most parts of the world including South Asia region.
Moreover, a very few studies have been published from
this region regarding Her-2/neu expression in colorectal
adenocarcinoma [13–15]. Therefore, in this study we
attempted to know the expression of Her-2/neu in colo-
rectal tumors in our population which might prove in
future a useful prognostic factor and worthy therapeutic
target for colorectal carcinoma.
Methods
Recruitment of patients and ethical approval
The study was conducted at the Dow Diagnostic Re-
search and Reference Laboratory (DDRRL), Dow Univer-
sity of Health Sciences (DUHS), Karachi after ethical
approval of Institutional Review Board during August
2014 to February 2016. A total of 95 patients with colo-
rectal carcinoma who underwent colorectal cancer
biopsy at National Institute of Liver and Gastrointestinal
Diseases (NILGID) and colectomy at surgical ward of
DUHS were recruited in the study after their informed
consent. Clinico-pathological parameters of the patients
were then recorded.
Processing of tissues and microscopy
Subsequent to biopsy/colectomy, specimens were trans-
ferred to the Histology section in 10 % neutral buffer
formalin. Samples were examined for gross features and
paraffin blocks were prepared for subsequent staining
and microscopy. Tissue sections, each measuring 3 to
4 μm in thickness were cut from the paraffin blocks and
processed for H&E staining. Based on microscopic
examination of the H&E stained slides, clinico-
pathological parameters were recorded including tumor
type, tumor grade amongst others. Histopathological
grading of tumors was performed according to the
World Health Organization (WHO) criteria as grade I
(well differentiated), grade II (moderately differentiated)
and grade III (poorly differentiated). Pathological staging
of colectomy cases were recorded as per the 7th edition
of the American Joint Committee on Cancer Staging
(stage I to stage IV) [16].
Immunohistochemistry and scoring of Her-2/neu over-
expression
In order to investigate expression of Her-2/neu in colo-
rectal adenocarcinoma, conventional immunhohisto-
chemistry protocol was subjected on all cases. Sections
were deparaffinized, dehydrated and antigen retrieval
was performed. Further, the sections were incubated
with the mouse primary monoclonal antibody against
Her-2/neu (clone CB-11, dilution 1:65, Cellmarque) for
1 h in the moisturisation chamber. Secondary antibody
(Hi-Def detection system) (Cellmarque) containing so-
lution A as amplifier and solution B as polymer was
used. For all read-outs, staining was controlled by
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using known Her-2/neu over-expressing breast carcin-
oma tissues.
Her-2/neu stained slides were independently evaluated
by two experienced pathologists. In order to quantify/
score Her-2/neu expression, three criterias were
followed [17]:
1. Pattern of Her-2/neu expression: Membranous/
cytoplasmic/membranous + cytoplasmic
2. Intensity of staining: Weak/moderate/strong
3. Percentage of cells stained:
10-40 % cells stained as score 1+
40-70 % cells stained as score 2+
>70 % cells stained as score 3+
Statistical analysis
Data was recorded for different variables including age
and gender of the patients, histopathological type, grade,
stage of the tumor and Her-2/neu expression and
analysed using SPSS version 21. In order to investi-
gate association of Her-2/neu expression in colorectal
adenocarcinomas with other categorical variables,
Chi-square or Fisher’s exact test were applied. A p-
value < 0.05 was considered as significant.
Results
Clinico-pathological parameters of colorectal cancer
patients
The study included a total of 95 cases of colorectal
adenocarcinoma. Mean age of the patients recruited in
this study was 46 years (range22-85 years). Of all the pa-
tients studied, a total of 51 (53.7 %) were males while 44
(46.3 %) were females. A total of 74 (77.9 %) were biopsy
specimens while 21 (22.1 %) were colectomy specimens.
Overall, a total of 14 (14.7 %) patients had grade I, 59
(62.1 %) had grade II and 22 (23.2 %) had grade III tumors.
Histologically, 13 (13.7 %) tumors were mucinous and 82
(86.3 %) were non mucinous variants. Pathological staging
could only be performed on colectomy samples (n = 21).
A total of 9 (42.9 %) cases were of stage IIA, 1 (4.8 %) case
of stage IIB, 2 (9.5 %) cases of stage IIIA, 3 (14.3 %) cases
of stage IIIB & 6 (28.6 %) cases of stage IIIC.
Her-2/neu Immunoreactivity in Colorectal Cancer
Of the total 95 colorectal cancer tissues, 75 (78.9 %)
showed Her-2/neu staining. Out of the total 75 positive
cases, 20 (26.6 %) showed membranous Her-2/neu ex-
pression, 36 (48 %) cases showed cytoplasmic expression
and 19 (25.3 %) cases showed membranous + cytoplas-
mic expression.
Of the total 75 positive cases, 19 (25.3 %) cases
showed weak intensity, 35 (46.6 %) showed moderate in-
tensity & 21 (28 %) showed strong intensity of Her-2/
neu staining.
Of the total 75 positive cases, 23 (30.6 %) were scored
as 1+, 18 (24 %) cases were scored as 2+ & 34 (45.3 %)
were scored as 3 + .
A statistically significant difference was seen between
pattern of Her-2/neu staining & grades of colorectal can-
cer (p-value = 0.038) (Fig. 1). Membranous Her-2/neu
staining was maximum in high grade while cytoplasmic
staining was more frequent in low grade colorectal can-
cer. Moreover, we observed that the frequency of mem-
branous Her-2/neu over expression increased with
grades of tumor while cytoplasmic over expression de-
creased from low to high grade colorectal cancer. A sta-
tistically significant association was observed between
pattern of Her-2/neu staining & type of colorectal cancer
depicting membranous Her-2/neu staining more com-
mon in mucinous while cytoplasmic more frequent in
non mucinous type of colorectal cancer (p-value =
0.024). No significant difference was noted between
pattern of Her-2/neu staining with age of the patient
& stage of the tumor (Table 1).
There was no significant association between intensity
of Her-2/neu staining with clinicopathological variables
(Table 2).
We observed a significant association between per-
centage of cells stained & tumor type, with score 3+
maximum in non mucinous type of colorectal cancer
(p-value = 0.006 (Table 3)).
Discussion
In this study our focus was to evaluate Her-2/neu
expression in colorectal adencarcinoma and to correlate
it with various clinicopathological variables. Various re-
search groups have investigated the expression patterns of
Her-2/neu in colorectal carcinomas with a variability ran-
ging from 0 to 84 % [9]. Average membranous expression
of Her-2/neu in colorectal cancer is about 5 % while cyto-
plasmic expression ranges between 0-66 % with an average
of 30 % [9]. These variable data could be attributed to sev-
eral factors including use of different antibodies, different
sample size, and use of non-uniform scoring system for
interpretation of results amongst others [9]. We have
highlighted some of the studies done in the past which ob-
served correlation between Her-2/neu expression in colo-
rectal cancer & grade and stage of tumor using different
antibodies (Table 4). Hence, to avoid the inconsistency in
results and for better reporting of Her-2/neu expression in
colorectal carcinoma a standardized protocol is urgently
in need. In breast cancer, Her-2/neu scoring follows
Hercep test where membranous expression of Her-2/
neu is evaluated by a cumulative score based on in-
tensity of reactivity, complete or incomplete staining
& percentage of cells stained [18]. In gastric cancer,
Hofmann Validation scoring is recommended for
membranous expression of Her-2/neu [19]. Whereas
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in colorectal cancer, a validated scoring has not been
established yet. However, there are few studies which
followed the three criterias related to Her-2/neu stain-
ing pattern, intensity and percentage of cells stained
[15, 17, 20].
Our study observed majority of colorectal cancers with
cytoplasmic expression of Her-2/neu (48 %) which cor-
responds to the studies which followed all the three pa-
rameters of Her-2/neu evaluation [15, 17, 20, 21]. In our
series we found 26.6 % positivity for membranous Her-
Table 1 Pattern of Her-2 staining in colorectal cancer
Pattern of Her-2 staining n(%) p-value
Negative Memb Cyto M + C
Gender F 44 7 (15.9) 4 (9.1) 21 (47.7) 12 (27.3) 0.013*
M 51 13 (25.5) 16 (31.4) 15 (29.4) 7 (13.7)
Age ≤60 year 70 15 (21.4) 16 (22.9) 24 (34.3) 15 (21.4) 0.666*
>60 year 25 5 (20.0) 4 (16.0) 12 (48.0) 4 (16.0)
Grade I 14 3 (21.4) 1 (7.1) 7 (50.0) 3 (21.8) 0.038**
II 59 11 (18.6) 9 (15.3) 25 (42.4) 14 (23.7)
III 22 6 (27.3) 10 (45.5) 4 (18.2) 2 (9.1)
Type Mucinous 13 5 (38.5) 5 (38.5) 1 (7.7) 2 (15.4) 0.024**
Nonmucinous 82 15 (18.3) 15 (18.3) 35 (42.7) 17 (20.7)
pTNM IIA 9 3 (37.5) 2 (50.0) 1 (80.0) 0 0.116**
IIB 1 1 (100) 0 0 0
IIIA 2 2 (100) 0 0 0
IIIB 3 1 (33.3) 1 (33.3) 1 (33.3) 0
IIIC 6 1 (16.7) 2 (33.3) 0 3 (50.0)
*Pearson Chi square, ** Fisher’s exact, level of significance at < 0.05
(Age ≤ 60 = age less than or equal to 60 years)
Fig. 1 a Control (normal colonic mucosa). b Membranous expression of Her-2/neu in colorectal adenocarcinoma. c Cytoplasmic expression of
Her-2/neu in colorectal adenocarcinoma. d Membranous + cytoplasmic expression of Her-2/neu in colorectal adenocarcinoma
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2/neu staining. On contrary to this, two studies from the
same region observed higher percentage of membranous
expression of Her-2/neu in colorectal carcinomas, 74.1 %
(n = 31) and 42 % (n = 100) respectively [13, 22, 23]. The
reason for the difference in the rate might be due to differ-
ent scoring protocols where they took into account only
the membranous expression of Her-2/neu staining and
did not consider the cytoplasmic expression. In the
present study, we found a significant association between
pattern of Her-2/neu staining & grade of colorectal cancer
which is in accordance with one of the study done in the
same region but to note here is that they compared the
significance of Her-2/neu expression in different grades
amongst different types of gastrointestinal carcinomas
(gastric, small intestine and colorectal carcinomas) and
did not primarily correlate the Her-2/neu expression
within different grades of colorectal carcinoma. Similarly,
the other study done in our area reported a significant
membranous Her-2/neu expression in low grade colorec-
tal carcinoma [13]. On contrary to this we noted
Table 2 Intensity of Her-2 staining in colorectal cancer
Intensity of Her-2 staining n(%) p-value
Negative Weak Mod Strong
Gender F 44 7 (15.9) 9 (20.5) 20 (45.5) 8 (18.2) 0.353*
M 51 13 (25.5) 10 (19,6) 15 (29.4) 13 (25.5)
Age ≤60 year 70 15 (21.4) 12 (17.1) 25 (35.7) 18 (25.7) 0.438*
>60 year 25 5 (20.0) 8 (32.0) 8 (32.0) 4 (16.0)
Grade I 14 3 (21.4) 4 (28.6) 4 (28.6) 3 (21.4) 0.514*
II 59 11 (18.6) 9 (15.3) 23 (39.0) 16 (27.1)
III 22 6 (27.3) 6 (27.3) 8 (36.4) 2 (9.1)
Type Mucinous 13 5 (38.5) 3 (23.1) 4 (30.8) 1 (7.7) 0.294**
Nonmucinous 82 15 (18.3) 16 (19.5) 31 (37.8) 20 (24.4)
pTNM IIA 9 3 (33.3) 3 (33.3) 3 (33.3) 0 0.267**
IIB 1 1 (100) 0 0 0
IIIA 2 2 (100) 0 0 0
IIIB 3 1 (33.3) 1 (33.3) 1 (33.3) 0
IIIC 6 1 (16.7) 1 (6.7) 1 (16.7) 3 (50.0)
*Pearson Chi square, ** Fisher’s exact, level of significance at < 0.05
(Age ≤ 60 = age less than or equal to 60 years)
Table 3 Percentage of Her-2 staining in colorectal cancer
Her-2 score n (%) p-value
0 1+ 2+ 3+
Gender F 44 7 (15.9) 10 (22.7) 10 (22.7) 17 (38.6) 0.592*
M 51 13 (25.5) 13 (25.5) 8 (15.7) 17 (33.3)
Age ≤60 year 70 15 (21.4) 14 (20.0) 15 (21.4) 26 (37.1) 0.408*
>60 year 25 5 (20.0) 9 (36.0) 3 (12.0) 8 (32.0)
Grade I 14 3 (21.4) 4 (28.6) 1 (7.1) 6 (4.9) 0.627**
II 59 11 (18.6) 12 (20.3) 13 (22.0) 23 (39.0)
III 22 6 (27.3) 7 (31.8) 4 (18.2) 5 (22.7)
Type Mucinous 13 5 (38.5) 5 (38.5) 3 (23.1)) 0 0.006**
Nonmucinous 82 15 (18.3) 18 (22.0) 15 (18.3) 34 (41.5)
pTNM IIA 9 3 (33.3) 4 (44.4) 2 (22.2) 0 0.028**
IIB 1 1 (100) 0 0 0
IIIA 2 2 (100) 0 0 0
IIIB 3 1 (33.3) 0 2 (66.7) 0
IIIC 6 1 (16.7) 1 (16.7) 0 4 (66.7)
*Pearson Chi square, ** Fisher’s exact, level of significance at < 0.05
(Age ≤ 60 = age less than or equal to 60 years)
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membranous Her-2/neu expression to be significantly as-
sociated with high grade colorectal cancer. As mentioned
earlier that these disagreements might be due to difference
in scoring protocol, where they observed only membran-
ous staining.
A study from West, conducted on 121 colorectal can-
cer cell lines for Her-2/neu expression, observed 63.5 %
cases with cytoplasmic expression and a significant asso-
ciation with low grade colorectal carcinoma [24]. Their
finding was similar to ours with respect to association
with grade of colorectal cancer. While, study from Iran
& India found significant association of cytoplasmic
Her-2 expression with high grade (100 %). This discrep-
ancy might be due to the fact that they had only two
cases classified under high grade cancer [15, 20, 24].
A very few studies attempted to study the intensity &
percentage of Her-2/neu staining where as similar to our
study they also depicted insignificant findings [15, 17, 20].
These studies suggest that in future focus should be made
on the pattern of Her-2/neu staining in colorectal carcin-
omas. Membranous Her-2/neu expression in colorectal
cancer could be a future extracellular therapeutic target by
Trastuzumab. An intracellular kinase inhibitor, Lapatinib
has been recently approved for Trastuzumab resistant
breast cancer patients [25]. Assuming the role of cytoplas-
mic Her-2/neu expression in pathogenesis of colorectal
carcinoma, Lapatinib could be advancement in the treat-
ment of colorectal cancer patients.
One of the limitation of our study was small sample size
of colectomy cases (n = 21) to investigate the association be-
tween pTNM & Her-2/neu expression. Although, a signifi-
cant association is seen between percentage of cells stained
with Her-2/neu & stage of tumor, this might have low statis-
tical power. Nevertheless, our study is an extensive effort
done in South Asia region which observed all the three pa-
rameters of Her-2/neu expression in colorectal carcinoma.
Conclusion
Our study concludes a high expression of Her-2/neu in
colorectal cancer in our population. A significant strong
association of cytoplasmic Her-2/neu expression with
low grades whereas membranous Her-2/neu expression
with high grade colorectal cancer. These findings may
help in conducting clinical trials in future to explore its
therapeutic significance as well.
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Table 4 Correlation of Her-2+/neu cases of colorectal carcinoma with tumor grade & stage
Author Antibody used Samples
(n)
Her-2 + ve (%) Grade Stage
M C M + C
Seo et al. [26] Monoclonal 4B5 365 6 - - NA NA
Gill et al. [15] Monoclonal RTU-CB11 40 - 57.5 7.5 II/III III/IV
Li et al. [27] Hercep test Kit 317 15.4 - - NS III
Anwar et al. [13] Monoclonal PY1248 100 42 - - I/II NS
Kruszweski et al. [21] Polyclonal A0485 202 26.7 66.3 - NA NA
Kafi et al. [17] Polyclonal K5204 69 - 27 14 I NA
Tavangar et al. [28] Monoclonal 55 - - 21.8 II/III III
M membranous, C cytoplasmic, M+ C membranous + cytoplasmic expression, NA not associated, NS not stated in the manuscript
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